-
Something wrong with this record ?
Antibiofilm activity and mode of action of DMSO alone and its combination with afatinib against Gram-negative pathogens
MFZR. Yahya, Z. Alias, SA. Karsani,
Language English Country United States
Document type Journal Article
- MeSH
- Anti-Bacterial Agents pharmacology MeSH
- Biofilms drug effects MeSH
- Quinazolines pharmacology MeSH
- Dimethyl Sulfoxide pharmacology MeSH
- Escherichia coli drug effects physiology MeSH
- Pseudomonas aeruginosa drug effects physiology MeSH
- Salmonella typhimurium drug effects physiology MeSH
- Spectroscopy, Fourier Transform Infrared MeSH
- Drug Synergism MeSH
- Publication type
- Journal Article MeSH
Biofilms are complex microbial communities that tend to attach to either biotic or abiotic surface. Enclosed in a self-produced extracellular polymeric substance (EPS) matrix, the biofilms often cause persistent infections. The objective of this study was to investigate the antibiofilm activity of dimethyl sulfoxide (DMSO) and afatinib against Gram-negative pathogens. Test microorganisms used in this study were Escherichia coli ATCC 1299, Pseudomonas aeruginosa ATCC 10145, and Salmonella typhimurium ATCC 14028. Biofilms were developed in 96-well microplate at 37°C for 24 h. Following removal of non-adherent cells, analysis of biofilm viability, biofilm biomass, and extracellular polymeric substances (EPS) matrix were performed using resazurin assay, crystal violet assay, and attenuated total reflectance fourier transform infrared (ATR-FTIR) spectroscopy, respectively. Bradford protein assay was conducted to determine the total amount of EPS proteins. The results demonstrated that both 32% DMSO alone and its combination with 3.2 μg/mL afatinib were effective in killing biofilm cells and reducing biofilm biomass. IR spectral variations of EPS matrix of biofilms in the range between 1700 and 900 cm-1 were also observed. Reduction in EPS proteins verified the chemical modifications of EPS matrix. In conclusion, 32% DMSO alone and its combination with 3.2 μg/mL afatinib showed remarkable antibiofilm activities against Gram-negative pathogens. It was suggested that the biofilm inhibition was mediated by the chemical modification of EPS matrix.
Institute of Biological Sciences Faculty of Science University of Malaya 50603 Kuala Lumpur Malaysia
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18026883
- 003
- CZ-PrNML
- 005
- 20180730110105.0
- 007
- ta
- 008
- 180730s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s12223-017-0532-9 $2 doi
- 035 __
- $a (PubMed)28540585
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Yahya, Mohd Fakharul Zaman Raja $u Institute of Biological Sciences, Faculty of Science, University of Malaya, 50603, Kuala Lumpur, Malaysia. fakharulzaman@salam.uitm.edu.my. Faculty of Applied Sciences, Universiti Teknologi MARA Shah Alam, 40450, Shah Alam, Malaysia. fakharulzaman@salam.uitm.edu.my.
- 245 10
- $a Antibiofilm activity and mode of action of DMSO alone and its combination with afatinib against Gram-negative pathogens / $c MFZR. Yahya, Z. Alias, SA. Karsani,
- 520 9_
- $a Biofilms are complex microbial communities that tend to attach to either biotic or abiotic surface. Enclosed in a self-produced extracellular polymeric substance (EPS) matrix, the biofilms often cause persistent infections. The objective of this study was to investigate the antibiofilm activity of dimethyl sulfoxide (DMSO) and afatinib against Gram-negative pathogens. Test microorganisms used in this study were Escherichia coli ATCC 1299, Pseudomonas aeruginosa ATCC 10145, and Salmonella typhimurium ATCC 14028. Biofilms were developed in 96-well microplate at 37°C for 24 h. Following removal of non-adherent cells, analysis of biofilm viability, biofilm biomass, and extracellular polymeric substances (EPS) matrix were performed using resazurin assay, crystal violet assay, and attenuated total reflectance fourier transform infrared (ATR-FTIR) spectroscopy, respectively. Bradford protein assay was conducted to determine the total amount of EPS proteins. The results demonstrated that both 32% DMSO alone and its combination with 3.2 μg/mL afatinib were effective in killing biofilm cells and reducing biofilm biomass. IR spectral variations of EPS matrix of biofilms in the range between 1700 and 900 cm-1 were also observed. Reduction in EPS proteins verified the chemical modifications of EPS matrix. In conclusion, 32% DMSO alone and its combination with 3.2 μg/mL afatinib showed remarkable antibiofilm activities against Gram-negative pathogens. It was suggested that the biofilm inhibition was mediated by the chemical modification of EPS matrix.
- 650 _2
- $a antibakteriální látky $x farmakologie $7 D000900
- 650 _2
- $a biofilmy $x účinky léků $7 D018441
- 650 _2
- $a dimethylsulfoxid $x farmakologie $7 D004121
- 650 _2
- $a synergismus léků $7 D004357
- 650 _2
- $a Escherichia coli $x účinky léků $x fyziologie $7 D004926
- 650 _2
- $a Pseudomonas aeruginosa $x účinky léků $x fyziologie $7 D011550
- 650 _2
- $a chinazoliny $x farmakologie $7 D011799
- 650 _2
- $a Salmonella typhimurium $x účinky léků $x fyziologie $7 D012486
- 650 _2
- $a spektroskopie infračervená s Fourierovou transformací $7 D017550
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Alias, Zazali $u Institute of Biological Sciences, Faculty of Science, University of Malaya, 50603, Kuala Lumpur, Malaysia.
- 700 1_
- $a Karsani, Saiful Anuar $u Institute of Biological Sciences, Faculty of Science, University of Malaya, 50603, Kuala Lumpur, Malaysia. saiful72@um.edu.my.
- 773 0_
- $w MED00011005 $t Folia microbiologica $x 1874-9356 $g Roč. 63, č. 1 (2018), s. 23-30
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28540585 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180730 $b ABA008
- 991 __
- $a 20180730110416 $b ABA008
- 999 __
- $a ok $b bmc $g 1322109 $s 1023814
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 63 $c 1 $d 23-30 $e 20170524 $i 1874-9356 $m Folia microbiologica $n Folia microbiol. (Prague) $x MED00011005
- LZP __
- $a Pubmed-20180730